⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31623264 | 1.00 | HSD11B1 (0.33) | — | |
| SCHEMBL2449286 | 0.91 | EPHX2 (0.31) | — | |
| SCHEMBL13841224 | 0.91 | POLB (0.32) | — | |
| SCHEMBL15199170 | 0.91 | POLB (0.32) | — | |
| SCHEMBL2451916 | 0.91 | EPHX2 (0.31) | — | |
| SCHEMBL2449282 | 0.91 | EPHX2 (0.31) | — | |
| SCHEMBL12332814 | 0.91 | POLB (0.32) | — | |
| SCHEMBL17115667 | 0.91 | — | — | |
| SCHEMBL1340689 | 0.91 | RIPK1 (0.35) | — | |
| SCHEMBL1341780 | 0.91 | CES2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115784857-A | 4-fluorophenyl cyclopropyl ketone- 14 C and preparation method thereof | 长沙贝塔医药科技有限公司 | 2023-03-14 | — | — | CN | claimed |
| US-12612412-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4720064-A1 | FUSED AZOLED AS TYK2 INHIBITORS AND USES THEREOF | Sudo Biosciences Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | KARUNA THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | KOJIN THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12509470-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4665458-A1 | INHIBITING ALPHA V BETA8 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12421242-B2 | Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions | Karuna Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250282788-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250243196-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| US-5919810-A | SEPTIC SHOCK | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | disclosed |
| US-5919943-A | INHIBITION OF SPLA2 | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | disclosed |
| EP-0868182-A4 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | ALBANY MOLECULAR RES INC (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0868182-A1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | ALBANY MOLECULAR RESEARCH, INC. (US) | 1998-10-07 | — | — | EP | disclosed |
| US-5733923-A | SECRETORY PANCREATIC PHOSPHOLIPASE A2 | ELI LILLY AND COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| US-5684034-A | INHIBITORS OF HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2, TREATMENT OF SEPTIC SHOCK, TRAUMA, RESPIRATORY DISORDERS, RHEUMATIC ARTHRITIS, INHIBITORS OF ARACHIDONIC ACID RELEASE | ELI LILLY AND COMPANY (US) | 1997-11-04 | — | — | US | disclosed |
| US-5654326-A | SEPTIC SHOCK; HUMAN NONPANCREATIC SECRETORY PHOSPHOLIPASE | ELI LILLY AND COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| WO-1997023213-A1 | PROCESS FOR PRODUCTION OF PIPERIDINE DERIVATIVES | ALBANY MOLECULAR RESEARCH, INC. (US) | 1997-07-03 | — | — | WO | disclosed |
| EP-0675110-A1 | 1H-Indole-3-glyoxylamide sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1995-10-04 | — | — | EP | disclosed |
| EP-0620215-A1 | 1H-indole-3-acetamide derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |